Entest BioMedical Obtains Specimen to Be Used in Immunotherapeutic Cancer Vaccine Research

Entest BioMedical Inc. (OTCBB: ENTB) Obtains Specimen to Be Used in Immunotherapeutic Cancer Vaccine Research
Entest Sees Stem Cells Derived From Tumor Research Specimens as Key Component in Elimination of Cancer; Specimens to Play Major Role Towards Establishment of Tumor Bank and Cancer Research Center With Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN)

Entest BioMedical Inc. (OTCBB: ENTB) announced it has obtained its first tumor specimen, a canine parathyroid tumor to be utilized in the development of Entest's immunotherapeutic cancer vaccine. According to Dr. Steven Josephs, lead cancer researcher for Entest, "Stem cells derived from tumors appear to be key components for creating an immunotherapeutic tumor vaccine. Inducing a patient's immune system to attack cancer stem cells may be a key step in complete elimination of the cancer."

Company Chairman David Koos said, "This is a major step in moving forward in the development of our immunotherapeutic cancer vaccine. Initially we will focus on treatment of cancer in canines, with the goal being eventually to extend our treatment model to humans. According to the National Canine Cancer Foundation, one out of every three dogs will develop cancer." The Company anticipates moving into human clinical trials once efficacy is established in the treatment of canines.

Koos also stated that, "Obtaining this specimen also represents a step forward towards our goal of jointly establishing a tumor bank and cancer research center with Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), the company's largest shareholder."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company is also involved in the development of medical devices (including stem cell extraction instrumentation).

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) is the largest shareholder of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, and aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

David R. Koos
Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax
Entest BioMedical Inc.
Email Contact
Follow the Company's progress on Twitter: